Multi-Channel Communication for Improvements in Cancer Education and Outcomes (MICEO) in Underserved Populations

项目摘要 儿童癌症幸存者是HPV疫苗接种的高度优先，服务不足的人群。他们不太 与一般人群相比，更有可能接种疫苗，并且更有可能发展为第二种 HPV引起的癌症。圣裘德综合癌症中心（SJCCC）是唯一的定位， 通过利用儿童癌症幸存者中HPV疫苗接种覆盖率的差异来解决观察到的差异 我们独特的覆盖范围遍及我们的集水区，并建立在屡获殊荣的，最先进的通信 与那些在SJCCC治疗的人及其家人一起。拟议行政管理的总体目标 补充是为了提高儿童癌症幸存者的HPV疫苗接种覆盖率。具体目标是 （1）开展创新的、有文化针对性的、多渠道的教育运动， 与HPV疫苗接种有关的扫盲，并提高儿童癌症中HPV疫苗接种的覆盖率 （2）对多渠道教育运动进行试点测试，以了解其对知识的影响， 并告知下一步的行动。我们提出的计划将建立在建立和新开发的病人 家庭和面向幸存者的英语和西班牙语教育资源， 传播，以促进和促进卫生知识普及。我们的方法将是高度迭代的， 圣裘德主要办事处的参与，包括SJCCC社区外展和参与，HPV 癌症预防计划，战略沟通，教育和外展，以患者家庭为中心 护理、患者体验办公室、过渡肿瘤学项目、治疗完成后诊所等 重要的是，通过我们与患者家属和儿童癌症幸存者的定期互动， 患者家庭咨询理事会和其他患者家庭顾问。多渠道宣传活动将重点 在基于网络的资源和社区，社交媒体平台，我们的圣裘德移动的应用程序（应用程序）， 传统的打印格式、用于处方患者教育的电子病历提示，以及点对点， 患者家庭冠军体验。我们将以10-30岁年龄组为目标， 按父母/照顾者为之作出接种决定的10-17岁儿童和18-30奥尔兹区分 在大多数情况下，他们可以自己决定接种疫苗。我们将开发和试点测试一种HPV 通过这些多渠道开展疫苗接种活动。我们的项目活动将被记录和监控 通过全面的过程评估。我们的努力的初步影响也将使用 定性、定量和分析数据，包括评估HPV疫苗接种率 以及在运动实施期之后。我们的努力将与圣裘德通信保持一致， 教育资源从一开始就优化可持续性。我们将公开分享我们的发现， 其他癌症中心和组织为儿童癌症幸存者服务，并继续完善和测试我们的 确保我们通过增加儿童HPV疫苗接种覆盖率来实现影响的方法 癌症幸存者

PROJECT ABSTRACT Childhood cancer survivors are a high-priority, underserved population for HPV vaccination. They are less likely to be vaccinated when compared to the general population and are more likely to develop second cancers caused by HPV as adults. St. Jude Comprehensive Cancer Center (SJCCC) is uniquely positioned to address observed disparities in HPV vaccination coverage among childhood cancer survivors by leveraging our unique reach across our catchment area and building on award-winning, state-of-the-art communication systems with those treated at SJCCC and their families. The overall goal of the proposed administrative supplement is to improve HPV vaccination coverage among childhood cancer survivors. The specific aims are to: (1) develop an innovative, culturally targeted, multi-channel educational campaign to enhance health literacy related to HPV vaccination and to improve HPV vaccination coverage among childhood cancer survivors; and (2) pilot test the multi-channel educational campaign to understand its impact on knowledge and intention and to inform the next steps. Our proposed plan will build on established and newly developed patient families and survivor-facing educational resources in English and Spanish, which are designed and disseminated to promote and facilitate health literacy. Our approach will be highly iterative and include engagement of key offices within St. Jude, including SJCCC Community Outreach and Engagement, HPV Cancer Prevention Program, Strategic Communication, Education and Outreach, Patient Family Centered Care, Patient Experience Office, Transition Oncology Program, After Completion of Therapy Clinic, and most importantly, through our regular interaction with patient families and childhood cancer survivors through the Patient Family Advisory Council and additional patient family advisors. The multi-channel campaign will focus on web-based resources and communities, social media platforms, Our St. Jude mobile application (app), traditional print formats, electronic medical record prompts for prescribed patient education, and peer-to-peer, patient family champion experiences. We will target the 10-30-year-old age group with approaches differentiated by 10-17-year-olds for whom parent/caregivers make vaccination decisions and 18-30-year olds who can make vaccination decisions for themselves, in most instances. We will develop and pilot test an HPV vaccination campaign across these multiple channels. Our project activities will be documented and monitored through a comprehensive process evaluation. The preliminary impact of our efforts will also be measured using qualitative, quantitative, and analytical data, including assessment of aggregated HPV vaccination rates before and after the campaign implementation period. Our efforts will be aligned with St. Jude communication and educational resources from the beginning to optimize sustainability. We will openly share our findings with other cancer centers and organizations serving childhood cancer survivors and continue to refine and test our approaches to ensure we are achieving impact through increased HPV vaccination coverage among childhood cancer survivors.